Rare disease drug developers struggle to survive in a biopharma investment market that prioritizes large patient populations.

P4ML’s Expertise in Genomic Patient Identification, Ties to Middle East Health Initiatives and Irish Biopharmaceutical Roots ...

P4ML, a Future100 company headquartered in the UAE, has been named a Founding Member of the Orphan Therapeutics Accelerator (OTXL), expanding OTXL's international capabilities in genomic patient ...

Announcement reinforces SGS’s position as one of the few European CROs offering end-to-end human ADME programs This ...

Recently Nasdaq-Listed Company Introduces Longevity Blood Test Integrating Inflammatory Biomarkers, Dietary Habits, and ...

Slate Medicines has emerged with hopes of cracking the code for delivering an injectable novel drug class to prevent ...

Scientists have created a blood test that can estimate when Alzheimer’s symptoms are likely to begin. By measuring a protein called p-tau217, the model predicts symptom onset within roughly three to ...

By analyzing a blood sample, scientists were able to estimate when a person’s Alzheimer’s symptoms would begin, often years ...

Centauri Therapeutics, a Cheshire-based immunotherapy company, has secured £6m from the AMR Action Fund, extending the firm's Series A round to £30m.

Clinical candidate in ABX-01 programme, CTX-187, currently in development ahead of first in-human clinical trials to target Gram-negative bacterial infections -- Investment from the world's largest ...

Slate Medicines, Inc., a privately-held biotech company advancing next-generation therapeutics for headache disorders, today announced the close of a $130 million Series A financing, alongside the ...